Effect of Ramipril on Renal Function in Patients with Intermittent Claudication

Overview

Journal Vasc Health Risk Manag

Publisher Dove Medical Press

Specialty Cardiology & Vascular Diseases

Date 2008 Jun 20

PMID 18561523

Authors

Simon D Hobbs

Martin W Claridge

Antonius B M Wilmink

Donald J Adam

Mark E Thomas

Andrew W Bradbury

Affiliations

Soon will be listed here.

Abstract

Background: The Heart Outcomes Prevention Study (HOPE) demonstrated that ramipril resulted in a blood-pressure-independent 25% reduction in cardiovascular events in patients with peripheral arterial disease (PAD). Despite this, general practitioners and vascular surgeons remain reluctant to prescribe ACE inhibitors in this group of patients because of concerns about renal artery stenosis (RAS). We aimed to define the effect of ramipril on renal function in patients with intermittent claudication (IC).

Methods And Results: Of 132 unselected patients with IC entering the study 78 (59%) were excluded due to: current ACE inhibitor use (38%), renal impairment (serum creatinine above normal range) (15%), known severe RAS (1%) or unwillingness to participate (5%). The remaining 54 patients were titrated to 10 mg ramipril and renal function was monitored at 1, 5, and 12 weeks. Treatment was discontinued during titration in 5 patients due to symptoms (3) or lack of compliance (2). In the remainder, median [IQR] serum creatinine increased (94 [85.8-103.3] to 98 [88.0-106.5] micromol/L, p < or = 0.001) and median [IQR] GFR decreased (71.5 [64.6-82.3] to 68.7 [59.8-74.7] mL/min per 1.73 m2, p < or = 0.001) between baseline and 5 weeks. These changes were not considered clinically significant. By 12 weeks these values had returned almost to baseline (Cr 95.5 [88.0-103.25] micromol/L, GFR 71.8 [65.3-77.4] mL/min). No patient had a serum creatinine rise > 30%.

Conclusion: Most of patients with IC and a normal serum creatinine can be safely commenced on ramipril provided they are screened, titrated and monitored as described above. Studies in patients with borderline renal impairment (serum creatinine up to 30% above baseline) are on-going.

References

Norgren L, Hiatt W, Dormandy J, Nehler M, Harris K, Fowkes F . Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2006; 33 Suppl 1:S1-75. DOI: 10.1016/j.ejvs.2006.09.024. View

Choudhri A, Cleland J, Rowlands P, Tran T, McCarty M, Al-Kutoubi M . Unsuspected renal artery stenosis in peripheral vascular disease. BMJ. 1990; 301(6762):1197-8. PMC: 1664347. DOI: 10.1136/bmj.301.6762.1197. View

Burns P, Gough S, Bradbury A . Management of peripheral arterial disease in primary care. BMJ. 2003; 326(7389):584-8. PMC: 1125476. DOI: 10.1136/bmj.326.7389.584. View

Lamy A, Yusuf S, Pogue J, Gafni A . Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation. 2003; 107(7):960-5. DOI: 10.1161/01.cir.0000050600.49419.25. View

Pillay W, Kan Y, Crinnion J, Wolfe J . Prospective multicentre study of the natural history of atherosclerotic renal artery stenosis in patients with peripheral vascular disease. Br J Surg. 2002; 89(6):737-40. DOI: 10.1046/j.1365-2168.2002.02144.x. View

Bjorholt I, Andersson F, Kahan T, Ostergren J . The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study. J Intern Med. 2002; 251(6):508-17. DOI: 10.1046/j.1365-2796.2002.00990.x. View

Smith M, Neville A, Middleton J . Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study. Intern Med J. 2003; 33(9-10):414-9. DOI: 10.1046/j.1445-5994.2003.00455.x. View

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3):145-53. DOI: 10.1056/NEJM200001203420301. View

Salmon P, Brown M . Renal artery stenosis and peripheral vascular disease: implications for ACE inhibitor therapy. Lancet. 1990; 336(8710):321. DOI: 10.1016/0140-6736(90)91865-8. View

10.

Bakris G, Weir M . Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med. 2000; 160(5):685-93. DOI: 10.1001/archinte.160.5.685. View

11.

Hobbs S, Thomas M, Bradbury A . Manipulation of the renin angiotensin system in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2004; 28(6):573-82. DOI: 10.1016/j.ejvs.2004.08.003. View

12.

Iglesias J, HAMBURGER R, Feldman L, Kaufman J . The natural history of incidental renal artery stenosis in patients with aortoiliac vascular disease. Am J Med. 2000; 109(8):642-7. DOI: 10.1016/s0002-9343(00)00605-7. View

13.

Leng G, Fowkes F . The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol. 1992; 45(10):1101-9. DOI: 10.1016/0895-4356(92)90150-l. View

14.

Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002. View

15.

. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study.... Can J Cardiol. 1996; 12(2):127-37. View

16.

. Antiplatelet therapy in peripheral arterial disease. Consensus statement. Eur J Vasc Endovasc Surg. 2003; 26(1):1-16. DOI: 10.1053/ejvs.2002.1927. View

17.

Missouris C, Buckenham T, Cappuccio F, Macgregor G . Renal artery stenosis: a common and important problem in patients with peripheral vascular disease. Am J Med. 1994; 96(1):10-4. DOI: 10.1016/0002-9343(94)90109-0. View